Total joint arthroplasty (TJA) is a procedure frequently performed for the treatment of end-stage joint osteoarthritis. The combined incidence of primary total knee arthroplasty (TKA) and total hip arthroplasty (THA) in the United States in 2010 was greater than 1 million, with a further 100,000 cases of revision knee and hip arthroplasties; this number is projected to increase with the aging population.^[@R1][@R2][@R3]^ Furthermore, it is estimated that the prevalence of corticosteroid use in the United States is nearly 1.2%.^[@R4]^ A number of patients presenting for TJA, such as those with rheumatoid arthritis, have comorbidities that are managed with chronic corticosteroid use resulting in notable overlap between these patient populations.^[@R5],[@R6]^

Corticosteroids are used for chronic management of immune and inflammatory processes, but the same mechanisms that facilitate their anti-inflammatory and immunosuppressive effects also cause delayed wound healing.^[@R7],[@R8]^ Specifically, corticosteroids decrease the ability of immune cells to infiltrate wounds via downregulation of cytokines and adhesion proteins in the endothelium (intracellular adhesion molecule \[ICAM\]), decrease fibroblast proliferation, and decrease the ability to perform collagen remodeling.^[@R7],[@R9]^ These mechanisms are believed to contribute to the clinical finding that chronic corticosteroids result in poorer outcomes of surgical procedures, including TJAs.^[@R5],[@R6],[@R8],[@R10][@R11][@R12][@R13]^ Associated complications include an increased need for revision arthroplasty, increased risk of readmission, thromboembolism, mortality, urinary tract infection (UTI), and deep and superficial wound infections.^[@R6],[@R8],[@R10][@R11][@R12][@R13]^

Few studies have examined the independent risk factor of chronic corticosteroid use for perioperative complications after THA and TKA,^[@R12],[@R13]^ and none have examined a broad range of complications. Therefore, this study aims to determine if chronic corticosteroid utilization is associated with an increase in perioperative complications in THA, TKA, and revision knee and hip arthroplasty.

Methods {#s1}
=======

This was a retrospective analysis of prospectively collected data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database between 2010 and 2017. The ACS-NSQIP is a national database of 30-day postoperative morbidity and mortality outcomes from more than 500 institutions in the United States. The database includes more than 300 variables including preoperative, intraoperative, and postoperative variables. Because the ACS-NSQIP is a Health Insurance Portability and Accountability Act (HIPPA) compliant deidentified database, this study was exempt from Institutional Review Board (IRB) approval.

Patients who underwent TJA, including primary TKA, primary THA, revision TKA, and, revision THA, were identified using the following Current Procedural Terminology codes: 27447, 27130, 27134, 27137, 27138, 27486, and 27487. A total of 403,566 patients met the Current Procedural Terminology code search criteria, and none were excluded.

Patient characteristics included patient demographics, medical comorbidities, preoperative condition, and surgical variables. Patient demographics included sex and age. Medical comorbidities included obesity (body mass index \> 30), diabetes, current smoker within one year, pulmonary comorbidities (ventilator dependence within 48 hours before surgery or a history of chronic obstructive pulmonary disease), cardiac comorbidities (hypertension requiring medication or a history of congestive heart failure), renal comorbidities (history of acute renal failure or progressive renal insufficiency), currently requiring or on dialysis, and bleeding disorders. Preoperative conditions included American Society of Anesthesiologists (ASA) class ≥3, dyspnea at rest, poor functional status, weight loss, and patients who received preoperative transfusion of ≥1 unit of whole/packed red blood cells (RBC) in 72 hours before surgery.

The primary outcome measures for this study included mortality and perioperative complications occurring within 30 days after surgery. The perioperative complications reviewed were wound infection and complications, including surgical site infection, occurrence of deep incisional surgical site infection, occurrences of organ space surgical site infection, and wound dehiscence. Also included were pneumonia, occurrences of unplanned intubation, episode of venous thromboembolic event, failure to wean from the ventilator within 48 hours after surgery, UTI, postoperative cerebrovascular accident, cardiac arrest, myocardial infarction, deep vein thrombosis (DVT), sepsis, and readmission.

Univariate statistical analysis was performed on baseline characteristics and for mortality and perioperative complication measures. Statistical significance was set at *P* = 0.05. All statistical analysis were performed using the SAS University Edition using SAS Studio 3.8.

Results {#s2}
=======

In our cohort of 403,566 patients, 3.7% (14,774 of 403,566) were prescribed corticosteroids for a chronic medical condition. Some baseline patient characteristics were significantly different between patients who were prescribed corticosteroids and those who were not (Table [1](#T1){ref-type="table"}). Statistically significant differences in medical comorbidities included obesity (*P* \< 0.0001), pulmonary comorbidity (*P* \< 0.0001), cardiac comorbidity (*P* \< 0.0001), renal comorbidity (*P* = 0.0035), patients on dialysis (*P* \< 0.0001), and bleeding disorder (*P* \< 0.0001). Regarding preoperative patient characteristics, ASA class (*P* \< 0.0001), dyspnea at rest (*P* \< 0.0001), poor functional status (*P* \< 0.0001), weight loss (*P* \< 0.0001), and preoperative transfusion of ≥1 unit of whole/packed RBCs in 72 hours before surgery (*P* \< 0.0001) all were significantly different between the chronic corticosteroid and control groups.

###### 

Baseline Patient Characteristics in the Patients Prescribed Corticosteroids for a Chronic Condition and No Corticosteroid Use Groups, Including Medical Comorbidities at the Time of Surgery, Preoperative Condition, and Operative Variables

  Patient Characteristics    No Steroid Use (n = 388,792)   Steroid Use (n = 14,774)   *P* Value           
  -------------------------- ------------------------------ -------------------------- ----------- ------- ----------
  Sex                                                                                                      
   Male                      159,882                        41.12                      4,808       32.54   
   Female                    228,728                        58.83                      9,962       67.43   
  Age \> 65                  207,263                        53.31                      7,357       49.80   
  Medical comorbidities                                                                                    
   Obesity                   220,208                        56.64                      7,709       52.18   \<0.0001
   Diabetes                  61,778                         15.89                      2,334       15.80   0.7647
   Smoking                   40,045                         10.30                      1,562       10.57   0.2845
   Pulmonary comorbidities   13,894                         3.57                       1,231       8.33    \<0.0001
   Cardiac comorbidities     239,939                        61.71                      9,438       63.88   \<0.0001
   Renal comorbidities       577                            0.15                       36          0.24    0.0035
   Dialysis Dependent        675                            0.17                       75          0.51    \<0.0001
   Bleeding disorder         8,414                          2.16                       586         3.97    \<0.0001
  Preoperative condition                                                                                   
   ASA class \> 3            6,695                          1.72                       621         4.20    \<0.0001
   Dyspnea at rest           695                            0.180                      85          0.58    \<0.0001
   Poor functional status    6,067                          1.56                       474         3.21    \<0.0001
   Weight loss               565                            0.15                       53          0.36    \<0.0001
   Transfusion               22,521                         5.79                       1,233       8.35    \<0.0001
  Surgical variables                                                                                       
   Primary TKA               225,103                        57.90                      8,208       55.56   
   Primary THA               140,374                        36.11                      5,337       36.12   
   rTKA                      12,989                         3.34                       608         4.12    
   rTHA                      10,326                         2.66                       621         4.20    

ASA = American Society of Anesthesiologists, rTHA = revision total hip arthroplasty, rTKA = revision total knee arthroplasty, THA = total hip arthroplasty, TKA = total knee arthroplasty

The results of the univariate analysis are summarized in Table [2](#T2){ref-type="table"}. No statistically significant difference was observed in the 30-day mortality between the two groups. However, a statistically significant difference was observed in perioperative complications for patients prescribed corticosteroids, including higher rates of surgical site infection (*P* \< 0.0001), occurrence of deep incisional surgical site infection (*P* \< 0.0001), occurrences of organ space surgical site infection (*P* \< 0.0001), wound dehiscence (*P* \< 0.0001), general would infection (*P* \< 0.0001), pneumonia (*P* \< 0.0001), occurrences of unplanned intubation (0.0002), UTI (*P* \< 0.0001), and readmission (*P* \< 0.0001).

###### 

Univariate Analysis of 30-Day Perioperative Mortality and Morbidity in Patients Prescribed Corticosteroids for a Chronic Condition and No Corticosteroid Use

  Perioperative Complication                No Steroid Use (n = 388,792)   Steroid Use (n = 14,774)   *P* Value          
  ----------------------------------------- ------------------------------ -------------------------- ----------- ------ ----------
  Mortality                                 6                              0.0015                     0           0      0.6326
  Surgical site infection                   2,126                          0.55                       116         0.79   0.0001
  Deep incisional surgical site infection   727                            0.19                       54          0.37   \<0.0001
  Organ space surgical site infection       982                            0.25                       64          0.43   \<0.0001
  Wound dehiscence                          668                            0.17                       56          0.38   \<0.0001
  Any wound infection                       4,247                          1.09                       269         1.82   \<0.0001
  Pneumonia                                 1,212                          0.31                       117         0.79   \<0.0001
  Reintubation                              583                            0.15                       40          0.27   0.0002
  Venous thromboembolic event               1,672                          0.43                       57          0.39   0.4191
  Failure to wean off ventilator            249                            0.06                       14          0.09   0.151
  UTI                                       3,120                          0.80                       187         1.27   \<0.0001
  Postoperative cerebrovascular accident    349                            0.09                       19          0.13   0.1247
  Cardiac arrest                            297                            0.08                       17          0.12   0.098
  Myocardial infarction                     843                            0.22                       36          0.24   0.4921
  DVT                                       2,487                          0.64                       108         0.73   0.1728
  Sepsis                                    11                             0.003                      0           0      0.5179
  Readmission                               844                            0.22                       50          0.34   \<0.0001

DVT = deep vein thrombosis, UTI = urinary tract infection

Discussion {#s3}
==========

The aim of this study was to assess the risk of perioperative complications of TJA in patients on a regimen of corticosteroids for chronic disease. The results showed that patients undergoing chronic treatment with corticosteroids experienced a statistically significant increase in surgical site infection, deep incisional surgical site infection, organ space surgical site infection, wound dehiscence, general wound infection, pneumonia, reintubation, UTI, and readmission. However, these patients did not experience increased rates of overall mortality. We also found that the difference in baseline characteristics of patients taking regimens of chronic corticosteroids versus the control group were statistically significant, reflecting higher comorbidities in the corticosteroid group.

Our result of increased risk of perioperative infection in chronic corticosteroid users is consistent with previous findings.^[@R14][@R15][@R16][@R17]^ The goals of the previous studies were to identify risk factors for TJA infection rather than to identify complications related to chronic corticosteroid use. Therefore, previous publications do not differentiate between the types of infections caused by corticosteroids. Our results show that the rates of all types of surgical site infections are increased in TJA patients prescribed chronic corticosteroids. UTIs were also found at a higher rate in the population taking chronic corticosteroids. Although there is very little literature addressing nosocomial UTIs as a complication of arthroplasty, Alvarez et al^[@R18]^ did identify chronic corticosteroid use as an independent risk factor for UTI in TJA. There are also no known studies directed at exploring pneumonia as a complication of patients receiving chronic corticosteroids and receiving TJA. These complications are likely attributed to the immunosuppressive effects of corticosteroids. The decreased ability of the immune cells to infiltrate the surgical site leads to less immune activity and a greater likelihood that a pathogen will colonize the site.^[@R7],[@R9]^ The systematic effects of the drug also decrease immune function in the urinary tract and respiratory system, leading to increased risk of developing an UTI or pneumonia, respectively.

Wound dehiscence was also found to be increased by a statistically significant margin in patients taking chronic corticosteroids. No previous studies exist demonstrating the relationship between dehiscence and chronic corticosteroids in arthroplasty surgeries; however, there are studies that demonstrate an increased prevalence of wound dehiscence with corticosteroid use in other surgeries, such as abdominal and colorectal incisions.^[@R19],[@R20]^ Another study, completed by Ismael et al,^[@R8]^ used the ACS-NSQIP database and demonstrated an increase in wound dehiscence in chronic corticosteroid users across all types of surgery. This effect may be explained by the ability of corticosteroids to depress the proliferation of fibroblasts and inhibit the ability to remodel collagen.^[@R7],[@R9]^

It is also notable that mortality, venous thrombus emboli (VTE), failure to be weaned from ventilation after 48 hours, postoperative cerebrovascular accident, cardiac arrest, myocardial infarction, DVT, and sepsis did not occur at a statistically significant increased rate. There is literature that shows that high concentrations of cortisol is linked to higher prevalence of both VTE and DVT.^[@R21],[@R22]^ However, we found no evidence of increased risk for clotting events in our study. The only other investigation into postarthroplasty VTE and chronic corticosteroid use was also performed using the ACS-NSQIP database.^[@R13]^ The absence of an increased rate of perioperative sepsis is surprising. Although perioperative infection rates did increase with chronic corticosteroid use, the incidence of sepsis did not. Although there is no known literature assessing the risk of sepsis due to chronic steroid use in TJA, there are a few studies that show that there is an increased risk of sepsis in patients undergoing other surgeries who are on chronic corticosteroids.^[@R23],[@R24]^ The absence of an increased risk of sepsis may be due to the immunomodulating effects of corticosteroids; although some literature has demonstrated a decrease in mortality from septic shock among corticosteroid users,^[@R25]^ others have shown no difference in mortality rates.^[@R26]^ Therefore, further study is warranted to explore the relationship between postoperative TJA sepsis and chronic corticosteroid use.

This study is not without several limitations. First, the statistically significant differences existed in baseline characteristics between the control group and those who were on regimens of chronic corticosteroids. The goal of this study, however, is not to prove chronic corticosteroid use as an independent, causative risk factor for TJA complications. Instead, it demonstrates that patients receiving chronic corticosteroid treatment are associated with more comorbidities than the general population at baseline, and this population consequently features a higher risk for specific perioperative morbidities. This study is useful for surgeons, allowing them to consider a broader increased risk of specific perioperative complications in patients prescribed chronic corticosteroids. As with any large database study of this scale, it is difficult to eliminate mistakes in the recording of patient information, and a subset of patients may have been inadvertently included or excluded. Finally, there is a lack of data on the dose of corticosteroids taken by the patients. Further study in which patients are stratified by high- or low-dose chronic corticosteroids would be useful.

Conclusion {#s4}
==========

Corticosteroid use for a chronic condition for patients who underwent TJA were found to be independently associated with multiple perioperative complications. Further study of complication incidences in relation to corticosteroid use can help improve preoperative planning, optimization, and postoperative monitoring. Risk stratification can result in an improvement of postoperative complications.
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